← 返回

一例罕见的侵袭性播散性鼻型 EB 病毒阳性结外 NK/T 细胞淋巴瘤伴骨髓受累

英文原题:A Rare Case of Aggressive Disseminated Nasal-Type Epstein-Barr Virus-Positive Extranodal Natural Killer/T-Cell Lymphoma with Bone Marrow Involvement.

查看英文原题

A Rare Case of Aggressive Disseminated Nasal-Type Epstein-Barr Virus-Positive Extranodal Natural Killer/T-Cell Lymphoma with Bone Marrow Involvement.

PubMed 2023/06/18(内容时间) Am J Case Rep Q3 · IF 0.8(JCR 2025)

分数与星级只用于站内排序 —— 不代表疗效、安全性或个人适用性。

中文摘要

背景 鼻型结外NK/T细胞淋巴瘤(ENKL)是一种极为罕见且侵袭性强的非霍奇金淋巴瘤亚型。该恶性肿瘤发病率和死亡率均高,且最常见于疾病晚期患者中被发现。

因此,早期发现和治疗对于提高生存率和尽量减少持久影响至关重要。病例报告 本文报告一例鼻型ENKL女性患者,表现为面部疼痛及相关的鼻部和眼部溢液。

我们重点介绍了鼻咽部和骨髓活检的组织病理学特征,分别显示EB病毒阳性的弥漫性和细微受累生物标志物,并伴有相关的显色免疫组化染色。

我们还重点介绍了现有的化疗联合放疗以及巩固治疗方案,并提出需要进一步研究异基因造血干细胞治疗以及程序性死亡配体1(PD-L1)抑制在治疗鼻型ENKL恶性肿瘤中的潜力。结论 鼻型ENKL是一种罕见的非霍奇金淋巴瘤亚型,与骨髓受累关联不常见。该恶性肿瘤总体预后差,通常在疾病病程晚期才被发现。当前治疗倾向于采用综合治疗模式。

然而,既往研究在确定化疗或放疗能否单独使用方面结果不一致。此外,趋化因子调节剂,包括靶向PD-L1的拮抗药物,在难治性和晚期病例中也显示出有希望的结果。

展开英文摘要原文

BACKGROUND Nasal-type extranodal natural killer/T-cell lymphoma (ENKL) is an exceedingly rare and aggressive subtype of non-Hodgkin lymphoma. The malignancy has both a high morbidity and mortality and is most commonly discovered in patients with advanced stages of the disease. As a result, early detection and treatment is tantamount to improving survival and minimizing lasting effects. CASE REPORT Herein, we report a case of nasal-type ENKL in a woman with facial pain and associated nasal and eye discharge.

We highlight the histopathologic features from nasopharyngeal and bone marrow biopsy, which demonstrated Epstein-Barr virus-positive biomarkers of diffuse and subtle involvement, respectively, with associated chromogenic immunohistochemical staining.

We also highlight existing therapy utilizing a combination of chemotherapy with radiation, as well as consolidation therapy, and suggest the need for further research of allogeneic hematopoietic stem cell treatment and the potential of programmed death ligand 1 (PD-L1) inhibition in managing nasal-type ENKL malignancy.

CONCLUSIONS Nasal-type ENKL is a rare subtype of non-Hodgkin lymphoma that is infrequently associated with bone marrow involvement. The malignancy has a poor prognosis overall and typically is discovered late in the disease course. Current treatment favors utilization of combined modality therapy.

However, previous studies have been inconsistent in determining whether chemotherapy or radiation therapy can be used alone.

Additionally, promising results have also been shown with chemokine modulators, including antagonistic drugs that target PD-L1, in refractory and advanced cases.

论文信息

作者
Yee AC、Karim FW、Giashuddin SM、Grutman G
单位
Department of Internal Medicine, New York-Presbyterian Brooklyn Methodist Hospital, Brooklyn, NY, USA.United States
文献类型
病例报告
期刊
The American journal of case reports2023 Jun 18
原文标识
PubMed 37384825 · DOI 10.12659/AJCR.939286